The Real World Study of BTK Inhibitor in the Treatment of Chronic Lymphocytic Leukemia in China

ConditionCLL

Trial statusNot yet recruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18+

SponsorPeking University People's Hospital

About this trial

This is a Multicenter, Retrospective Real-world Study of Zanubrutinib in the Treatment of Chronic Lymphocytic Leukemia in China

Eligibility criteria

Qualifiers

Patients aged ≥18 years old

Must have a confirmed diagnosis of Chronic Lymphocytic Leukemia (CLL) requiring treatment (iwCLL [International Workshop on Chronic Lymphocytic Leukemia] criteria)；

Treatment-naïve OR Refractory Recurrence CLL patients who were initiated on BTK inhibitor;

Prior or current use of BTK inhibitor for ≥3 months

Disqualifiers

None

Trial design

Treatments tested in this trial

BTK inhibitor

Treatment groups

No treatment groups listed

Locations

This trial has no locations

Sponsors and collaborators

Peking University People's Hospital

Lead sponsor

Source ClinicalTrials.gov